<DOC>
<DOCNO>EP-0644878</DOCNO> 
<TEXT>
<INVENTION-TITLE>
2,5-DIOXO-2,5-DIHYDRO-1H-BENZ b]AZEPINES AS NMDA RECEPTOR ANTAGONISTS
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P2514	A61P2518	A61K3155	C07D40312	C07D22316	A61P2500	C07D40304	C07D40104	A61P2528	C07D22300	C07D40300	A61P2500	A61K3155	C07D40100	A61P2516	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	A61P	A61K	C07D	C07D	A61P	C07D	C07D	A61P	C07D	C07D	A61P	A61K	C07D	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P25	A61P25	A61K31	C07D403	C07D223	A61P25	C07D403	C07D401	A61P25	C07D223	C07D403	A61P25	A61K31	C07D401	A61P25	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Benz[b]azepines of formula (I) and (II), wherein R
<
1
>
, R
<
2
>
, R
<
3
>
 and R
<
4
>
 are independently selected from hydrogen, perfluoroalkyl, halo, nitro and cyano; R
<
5
>
 is selected from hydrogen and alkyl; R
<
6
>
 and R
<
7
>
 are independently selected from hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and CH2Y wherein Y is selected from (CHOH)nCH2OH and (CH2)mR
<
c
>
 whrein m is 0 to 5, n is 1 to 5 and R
<
c
>
 is selected from hydroxy, alkoxy, alkoxycarbonyl, carboxy, cycloalkyl, and NR
<
d
>
R
<
e
>
 in which R
<
d
>
 and R
<
e
>
 are independently selected from hydrogen and alkyl or R
<
d
>
 and R
<
e
>
, together with the nitrogen atom to which they are attached, form a 5-, 6- or 7-membered heterocyclic ring which optionally contains one additional heteroatom selected from nitrogen, oxygen and sulfur; or R
<
6
>
 and R
<
7
>
, together with the nitrogen atom to which they are attached, form a 5-, 6- or 7-membered heterocyclic ring which is bonded to said compound through said nitrogen atom, said heterocyclic ring optionally containing one additional heteroatom selected from nitrogen, oxygen and sulfur; R
<
8
>
 is selected from hydrogen, halo, alkyl which may optionally bear a substituent selected from amino, acylamino, carboxy and carboxamido, arylalkyl and heteroarylalkyl; and wherein each aryl or heteroaryl moiety may be optionally substituted; and pharmaceutically acceptable salt thereof, are useful in treating neurological disorders. Novel compounds and processes for their preparation are also referred to as well as the use of the compounds of formula (I) and (II) and pharmaceutical compositions containing them in treating neurological disorders.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<DESCRIPTION>
This invention relates to benz[b]azepine compounds useful in
the treatment of neurological disorders generally in mammals such as
man. More specifically, the compounds are useful in the treatment of
strokes and/or other neurodegenerative disorders such as hypoglycemia,
cerebral palsy, transient cerebral ischemic attack, perinatal
asphyxia, epilepsy, psychosis, Huntington's chorea, amyotrophic
lateral sclerosis, Alzheimer's disease, Parkinson's disease,
Olivo-pontocerebellar atrophy, viral-induced neurodegeneration such as
in acquired immunodeficiency syndrome and its associated dementia,
anoxia such as from drowning, spinal cord and brain trauma, poisoning
by exogenous neurotoxins, and chronic pain, for the prevention of drug
and alcohol withdrawal symptoms, and for the inhibition of tolerance
and dependence to opiate analgesics. The invention particularly
relates to novel benz[b]azepine compounds useful in reducing
neurological degeneration such as can be induced by a stroke and the
associated functional impairment which can result. Treatment using a
compound of the invention can be remedial or therapeutic as by
administering a compound following an ischemic event to mitigate the
effects of that event. Treatment can also be prophylactic or
prospective by administering a compound in anticipation that an
ischemic event may occur, for example in a patient who is prone to
stroke.It is known that ischemic events can trigger a dramatic
increase in extracellular concentrations of the excitatory amino acids
glutamate and aspartate which can, in turn, cause prolonged neuronal
excitation leading to a massive influx of calcium from extracellular
to intracellular sites in brain neural cells. A calcium overload can
thereby be created which leads to a cascade of events leading to cell
catabolism and eventually resulting in cell death. The N-methyl-D-aspartate
(NMDA) receptor complex is believed to play a significant
role in the cascade of events leading to cell necrosis following an
ischemic event.The compounds provided by this invention may be useful in a
variety of neurodegenerative disorders because they function as 
excitatory amino acid antagonists. They may do so indirectly, via
allosteric modulation of the glutamate binding site, specifically by
acting as antagonists of the strychnine-insensitive glycine receptor
on the NMDA receptor complex. They may also do so directly, by
binding to the glutamate site itself on the NMDA receptor complex.3-Amino-4-methyl-2,5-dioxo-2,5-dihydro-1H-benz[b]azepine is
disclosed
</DESCRIPTION>
<CLAIMS>
The use of a compound of formula I or a compound of formula II, for the
manufacture of a medicament for treating neurological disorders;



wherein

R
1
, R
2
, R
3
 and R
4
 are independently selected from hydrogen,
(1-3C)perfluoroalkyl, halo, nitro and cyano;
R
5
 is selected from hydrogen and (1-6C)alkyl;
R
6
 and R
7
 are independently selected from hydrogen, (1-6C)alkyl,
(2-6C)alkenyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl(1-6C)alkyl, aryl, aryl(1-6C)alkyl,

heteroaryl, heteroaryl(1-6C)alkyl and CH
2
Y wherein Y is selected from
(CHOH)
n
CH
2
OH and (CH
2
)
m
R
c
 wherein m is 0 to 5, n is 1 to 5 and R
c
 is selected
from hydroxy, (1-6C)alkoxy, (1-6C)alkoxycarbonyl, carboxy, and NR
d
R
e
 in which
R
d
 and R
e
 are independently selected from hydrogen and (1-4C)alkyl or R
d
 and R
e
,
together with the nitrogen atom to which they are attached, form a saturated 5-, 6- or

7-membered heterocyclic ring which optionally contains one additional heteroatom
selected from nitrogen, oxygen and sulfur; or R
6
 and R
7
, together with the nitrogen
atom to which they are attached, form a 5-, 6- or 7-membered heterocyclic ring which

is bonded to said compound through said nitrogen atom, said heterocyclic ring
optionally containing one additional heteroatom selected from nitrogen, oxygen and

sulfur, and wherein said heterocyclic ring may be substituted with 0-2 substituents 
selected from (1-6C)alkyl, phenyl, phenyl(1-4C)alkyl, phenoxy and

phenyl(1-4C)alkoxy;
R
8
 is selected from hydrogen, halo, (1-6C)alkyl which may optionally bear a
substituent selected from amino, (1-6C)acylamino, carboxy and carboxamido,

aryl(1-6C)alkyl and heteroaryl(1-6C)alkyl;
and wherein each aryl moiety is selected from phenyl and naphthyl; each
heteroaryl moiety is selected from 5- and 6-membered aromatic rings containing up to

3 heteroatoms independently selected from oxygen, sulfur, and nitrogen; and wherein
each aryl or heteroaryl moiety may be substituted with 0-2 substituents selected from

halo, cyano, hydroxy, carboxy, nitro, (1-6C)alkyl, (1-6C)alkoxy, (2-6C)alkenyl,
phenyl, phenyl(1-4C)alkyl, phenoxy, phenyl(1-4C)alkoxy and (1-6C)alkoxycarbonyl;
or a pharmaceutically acceptable salt thereof; provided that in compounds of
formula II, R
8
 is not hydrogen; and excluding the compound of formula II in which
R
1
-R
4
 are each hydrogen, R
8
 is bromo and R
5
 is hydrogen and its pharmaceutically
acceptable salt.
The use as claimed in claim 1 wherein the compound is of formula I and R
6

and R
7
 are independently selected from hydrogen, (1-6C)alkyl,
(3-7C)cycloalkyl(1-6C)alkyl, aryl, aryl(1-6C)alkyl, and heteroaryl(1-6C)alkyl and

CH
2
Y wherein Y is selected from (CHOH)nCH
2
OH and (CH
2
)mR
c
 wherein m is 0 to
5, n is 1 to 5 and R
c
 is selected from hydroxy, (1-6C)alkoxycarbonyl and NR
d
R
e
 in
which Rd and R
e
 are independently selected from (1-4C)alkyl, or R
6
 and R
7
, together
with the nitrogen atom to which they are attached, form a 5-, 6- or 7-membered

heterocyclic ring which is bound to said compound through said nitrogen atom, said
heterocyclic ring optionally containing one additional heteroatom selected from

nitrogen, oxygen and sulphur and wherein said heterocyclic ring may be substituted
with 0-2 substituents selected from (1-6C)alkyl, phenyl, phenyl(1-4C)alkyl, phenoxy

and phenyl(1-4C)alkoxy; and wherein an aryl or heteroaryl moiety may be substituted
with 0-2 substitutes selected from halo, cyano, hydroxy, carboxy, nitro, (1-6C)alkyl, 

(1-6C)alkoxy, (2-6C)alkenyl, phenyl, phenyl(1-4C)alkyl, phenoxy,
phenyl(1-4C)alkoxy and (1-6C)alkoxycarbonyl.
The use as claimed in claim 1 wherein:

R
1
, R
2
, R
3
 and R
4
 are independently selected from hydrogen and halo;
R
5
 is hydrogen or methyl;
R
6
 is selected from hydrogen, (1-6C)alkyl, aryl, aryl(1-6C)alkyl and CH
2
Y wherein
Y is selected from (CHOH)nCH
2
OH and (CH
2
)mR
c
 wherein m is 0 to 5, n is 1 to 5
and R
c
 is (1-6C)alkoxycarbonyl; and R
7
, is hydrogen or (1-6C)alkyl; or R
6
 and R
7
,
together with the nitrogen atom to which they are attached from a 5-, 6- or

7-membered heterocyclic ring which is bound to said compound through nitrogen
atom, and wherein said heterocyclic ring is selected from morpholino, imidazolyl,

pyrrolidinyl, pyrrolo, pyrazolyl, piperidinyl [which may optionally bear a
4-substituent selected from (1-6C)alkyl, phenyl(1-6C)alkyl, phenoxy and phenyl]
,
4-morpholinyl, piperazinyl [which may optionally bear a 4-substituent selected from

(1-6C)alkyl, phenyl(1-6C)alkyl and phenyl] and perhydroazepinyl; and wherein an

aryl is a phenyl and wherein an aryl or heteroaryl moiety may be substituted with 0-2
substituents selected from halo, hydroxy, carboxy, nitro, (1-6C)alkyl, (1-6C)alkoxy,

(2-6C)alkenyl, phenyl, phenyl(1-4C)alkyl, phenoxy, phenyl(1-4C)alkoxy and
(1-6C)alkoxycarbonyl; and
R
8
 is hydrogen, (1-6C)alkyl or iodo.
The use as claimed in claim 1 wherein:

R
1
, R
2
 and R
4
 are each hydrogen;
R
3
 is hydrogen or chloro;
R
5
 is selected from hydrogen and methyl;
the group -NR
6
R
7
 is selected from: amino, methylamino, dimethylamino,
diethylamino, phenethylamino, 4-morpholino, allylamino, Î±-methylbenzylamino,

t-butoxycarbonylmethylamino, 1-perhydroazepinyl, 1-pyrrolidinyl, anilino, pyrrolo, 
4-phenylpiperazin-1-yl, 4-benzylpiperazin-1-yl, piperidino,

2-(N,N-diethylamino)ethylamino, glucamino, 4-phenoxypiperidino, benzylamino,
cyclopropylmethylamino, 3,4-dibenzyloxyphenethylamino,

2-(4-imidazolyl)ethylamino, N,N-bis(2-hydroxyethyl)amino, and
N-(2-hydroxyethyl)amino;
R
8
 is selected from hydrogen, benzyl, methyl, 4-methoxycarbonylbenzyl and iodo.
The use as claimed in claim 1 wherein the compound is of formula II and R
5
 is
hydrogen.
The use of a compound of formula I, wherein:

R
1
, R
2
, R
3
 and R
4
 are independently selected from:
hydrogen,
(1-3C)perfluoroalkyl,
halo, nitro and cyano;

R
6
 and R
7
 are independently selected from

hydrogen,
CH
2
Y wherein Y is selected from (CH
2
)
m
OH and (CHOH)
n
CH
2
OH wherein
m is 0 to 5 and n is 1 to 5,
aryl, and aryl(1-6C)alkyl wherein each aryl moiety is selected from phenyl and
naphthyl each of which may be substituted with 0-2 substituenis selected from halo,

cyano hydroxyl, nitro, (1-6C)alkyl, (1-6C)alkoxy, vinyl, and allyl; and 
heteroaryl, and heteroaryl(1-6C)alkyl wherein each heteroaryl moiety is
selected from 5- and 6-membered aromatic rings containing up to 3 heteroatoms

independently selected from oxygen, sulfur, and nitrogen;
or R
6
 and R
7
, together with the nitrogen atom to which they are attached, form
a 5-, 6- or 7-membered heterocyclic ring which is bonded to said compound through

said nitrogen atom, said heterocyclic ring optionally containing one additional
heteroatom selected from nitrogen, oxygen and sulfur;
R
8
 is selected from
hydrogen,
(1-6C)alkyl which may optionally bear a substituent selected from amino,
(1-6C)acylamino, carboxy, and carboxamido; and
aryl(1-6C)alkyl;
or a pharmaceutically acceptable salt thereof;

for the manufacture of a medicament for treating neurological disorders.
A compound of formula I or formula II, and pharmaceutically acceptable salts
thereof, wherein:


R
1
, R
2
, R
3
 and R
4
 are independently selected from hydrogen,
(1-3C)perfluoroalkyl, halo, nitro and cyano;
R
5
 is selected from hydrogen and (1-6C)alkyl;
R
6
 and R
7
 are independently selected from hydrogen, (1-6C)alkyl,
(2-6C)alkenyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl(1-6C)alkyl, aryl, aryl(1-6C)alkyl,

heteroaryl, and heteroaryl(1-6C)alkyl and CH
2
Y wherein Y is selected from 
(CHOH)
n
CH
2
OH and (CH
2
)
m
R
c
 wherein m is 0 to 5, n is 1 to 5 and R
c
 is selected
from hydroxy, (1-6C)alkoxy, (1-6C)alkoxycarbonyl, carboxy, (3-7C)cycloalkyl, and

NR
d
R
e
 in which R
d
 and R
e
 are independently selected from hydrogen and (1-4C)alkyl
or R
d
 and R
e
, together with the nitrogen atom to which they are attached, form a 5-, 6-
or 7-membered heterocyclic ring which optionally contains one additional heteroatom

selected from nitrogen, oxygen and sulfur; or R
6
 and R
7
, together with the nitrogen
atom to which they are attached, form a 5-, 6- or 7-membered heterocyclic ring which

is bonded to said compound through said nitrogen atom, said heterocyclic ring
optionally containing one additional heteroatom selected from nitrogen, oxygen and

sulfur, and wherein said heterocyclic ring may be substituted with 0-2 substituents
selected from (1-6C)alkyl, phenyl, phenyl(1-4C)alkyl, phenoxy, phenyl(1-4C)alkoxy;
R
8
 is selected from hydrogen, halo, (1-6C)alkyl which may optionally bear a
substituent selected from amino, (1-6C)acylamino, carboxy and carboxamido,

aryl(1-6C)alkyl and heteroaryl(1-6C)alkyl;
and wherein each aryl moiety is selected from phenyl and naphthyl; each
heteroaryl moiety is selected from 5- and 6-membered aromatic rings containing up to

3 heteroatoms independently selected from oxygen, sulfur, and nitrogen; and wherein
each aryl or heteroaryl moiety may be substituted with 0-2 substituents selected from

halo, cyano, hydroxy, carboxy, nitro, (1-6C)alkyl, (1-6C)alkoxy, (2-6C)alkenyl,
phenyl, phenyl(1-4C)alkyl, phenoxy, phenyl(1-4C)alkoxy and (1-6C)alkoxycarbonyl;
provided that in compounds of formula II, R
8
 is not hydrogen; and
excluding the compound of formula II in which R
1
-R
4
 are each hydrogen, R
8
 is bromo
and R
5
 is hydrogen; the compounds of formula I wherein R
1
-R
4
 and R
6
-R
7
 are each
hydrogen and R
8
 is hydrogen or methyl; the compounds of formula I in which R
1
-R
4

and R
8
 are each hydrogen and R
6
 and R
7
, together with the nitrogen atom to which
they are attached, form a 5- or 6-membered ring; the compounds of formula I in which

R
1
-R
4
 and R
8
 are each hydrogen, R
6
 is hydrogen and R
7
 is CH
2
Y in which Y is 
(CH
2
)mR
c
 and R
c
 is NR
d
R
e
 in which R
d
 and R
e
 are (1-4C)alkyl; and their
pharmaceutically acceptable salts.
A compound of formula I as claimed in claim 7 wherein:

R
1
, R
2
, R
3
 and R
4
 are independently selected from hydrogen,
(1-3C)perfluoroalkyl, halo, nitro and cyano;
R
6
 and R
7
 are independently selected from hydrogen, (1-6C)alkyl,
(2-6C)alkenyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl(1-6C)alkyl, aryl, aryl(1-6C)alkyl,

heteroaryl, and heteroaryl(1-6C)alkyl and CH
2
Y wherein Y is selected from
(CHOH)
n
CH
2
OH and (CH
2
)
m
R
c
 wherein m is 0 to 5, n is 1 to 5 and R
c
 is selected
from hydroxy, (1-6C)alkoxy, (1-6C)alkoxycarbonyl, carboxy, and NR
d
R
e
 in which
R
d
 and R
e
 are hydrogen or R
d
 and R
e
, together with the nitrogen atom to which they
are attached, form a saturated 5-, 6- or 7-membered heterocyclic ring which optionally

contains one additional heteroatom selected from nitrogen, oxygen and sulfur; or
R
8
 is selected from hydrogen, halo, (1-6C)alkyl which may optionally bear a
substituent selected from amino, (1-6C)acylamino, carboxy and carboxamido,

aryl(1-6C)alkyl and heteroaryl(1-6C)alkyl;
and wherein each aryl moiety is selected from phenyl and naphthyl; each
heteroaryl moiety is selected from 5- and 6-membered aromatic rings containing up to

3 heteroatoms independently selected from oxygen, sulfur, and nitrogen; and wherein
each aryl or heteroaryl moiety may be substituted with 0-2 substituents selected from

halo, cyano, hydroxy, carboxy, nitro, (1-6C)alkyl, (1-6C)alkoxy, (2-6C)alkenyl,
phenyl, phenyl(1-4C)alkyl, phenoxy, phenyl(1-4C)alkoxy and (1-6C)alkoxycarbonyl;

but excluding the compounds wherein R
1
-R
4
 and R
6
-R
7
 are each hydrogen and R
8
 is
hydrogen or methyl; and pharmaceutically acceptable salts thereof.
A compound as claimed in claim 7 wherein the compound is of formula II,
wherein: 


R
1
, R
2
, R
3
 and R
4
 are independently selected from
hydrogen,
(1-3C)pcrfluoroalkyl,
halo, nitro and cyano;
R
5
 is hydrogen or (1-6C)alkyl;
R
8
 is selected from
(1-6C)alkyl which may optionally bear a substituent selected from amino,
(1-6C)acylamino, carboxy, and carboxamido; and
aryl(1-6C)alkyl;
and pharmaccutically acceptable salts thereof.
A compound of formula I as claimed in claim 7 wherein:

R
1
, R
2
, R
3
 and R
4
 arc independently selected from:

hydrogen,
(1-3C)perfluoroalkyl,
halo, nitro and cyano;
R
6
 and R
7
 are independently selected from
hydroben,
CH
2
Y wherein Y is selected from (CH
2
)
m
OH and (CHOH)
n
CH
2
OH wherein
m is 0 to 5 and n is 1 to 5,
aryl, and aryl(1-6C)alkyl wherein each aryl moiety is selected from phenyl and
naphthyl each of which may be substituted with 0-2 substituents selected from halo,

cyano, hydroxyl, nitro, (1-6C)alkyl, (1-6C)alkoxy, vinyl, and allyl; and
heteroaryl, and heteroaryl(1-6C)alkyl wherein each heteroaryl moiety is
selected from 5- and 6-membered aromatic rings containing up to 3 heteroatoms

independently selected from oxygen, sulfur, and nitrogen;
R
8
 is selected from
hydrogen, 
(1-6C)alkyl which may optionally bear a substituent selected from amino,
(1-6C)acylamino, carboxy, and carboxamido; and
aryl(1-6C)alkyl.
A compound as claimed in claim 6 which is selected from:

3-Amino-8-chloro-2,5-dioxo-2,5-dihydro-1H-benz[b]azepine;
3-Amino-2,5-dioxo-2,5-dihydro-1H-benz[b]azepine;
8-chloro-3-dimethylamino-2,5-dioxo-2,5-dihydro-1H-benz[b]azepine;
3-(4-benzylpiperazin-1-yl)-8-chloro-2,5-dioxo-2,5-dihydro-1H--benz[b]azepine;
8-chloro-3-(D-glucamino)-2, 5-dioxo-2,5-dihydro-1H-benz[b]azepine;
8-chloro-3-(2-[N,N-dimethylamino)ethyl]amino)-2,5-dioxo-2,5-dihydro--

1H-benz[b]azepine;
8-chloro-3-(4-phenoxypiperidino)-2,5-dioxo-2,5-dihydro-1H--benz[b]azepine;
8-Chloro-3-hydoxy-4-methyl-2, 5-dioxo-2,5-dihydro-1H-benz[b]azepine;
8-chloro-3-diethylamino-2,5-dioxo-2,5-dihydro-1H-benz[b]azepine; and
8-chloro-3-pyrrolo-2,5-dioxo-2,5-dihydro-1H-benz[b]azepine;
and pharmaceutically acceptable salts thereof.
A process for preparing a compound of formula I or of formula II as claimed in
claim 6, which process is selected from:


(a) for compounds of formula I, reacting a compound of formula II wherein R
5
 is
an alkyl group with an amine of formula R
6
R
7
NH;
(b) for compounds of formula I in which R
8
 is hydrogen, reacting a compound of
formula II in which R
8
 is halo with an amine of formula R
6
R
7
NH;
(c) for compounds of formula I or II in which R
8
 is halo, halogenating a compound
of formula I or II (as appropriate) in which R
8
 is hydrogen; 
(d) for compounds of formula II in which R
5
 is hydrogen, treating a compound of
formula II in which R
5
 is alkyl with a boron trihalide;
(e) for compounds of formula I or II in which R
8
 is other than hydrogen, reacting a
compound of formula I or II (as appropriate) in which R
8
 is halo with a compound of
formula R
8'
SnL
3
, in which L is a suitable ligand and R
8
' mat take any of the meanings
given in claim 1 for R
8
 except halo and hydrogen, in the presence of a suitable
catalyst;
(f) for those compounds of formula I in which -NR
6
R
7
 represents a pyrrolo group,
reacting a compound of formula I in which R
6
 and R
7
 are both hydrogen with a
2,5-dialkoxytetrahydrofuran; and
(g) for compounds of formula II in which R
8
 is other than hydrogen, reacting a
compound of formula II in which R
8
 is hydrogen with a compound of formula R
8
Z, in
which Z is a suitable leaving group, in the presence of a base;
and whereafter when a pharmaceutically acceptable salt is required,
reacting a compound of formula I or II with an acid affording a physiologically

acceptable anion, or reacting a compound of formula I or II with a base affording a
physiologically acceptable cation.
A pharmacuetical composition comprising a compound of formula I or of
formula II as defined in any one of claims 1 to 11, or a pharmaceutically acceptable salt

thereof, and a pharmaceutically acceptable diluent or carrier.
</CLAIMS>
</TEXT>
</DOC>
